Medigen Vaccines Biologics teamed with U.S. CDC to develop VLP vaccine for Dengue disease

, , , ,

On Dec. 14, 2016, Medigen Vaccine Biologics (MVC) amended an existing agreement with the National Institutes of Health (NIH) to expand dengue vaccine market territories from 17 countries to 26 countries in order to include Brunei, Cambodia, Laos, Myanmar, Papua New Guinea, and high dengue incidence areas like Sri Lanka, Bangladesh, Nepal and Bhutan.

VLP is self-assembling envelope or capsid protein mimicking the morphology of native virus without the infectious viral genome, making VLP non-infectious yet able to induce required immune response.

Tags:


Source: Medigen Vaccine Biologics
Credit: Photo: Transmission electron microscopic (TEM) image depicts a number of round, Dengue virus particles that were revealed in this tissue specimen, courtesy Frederick Murphy, Centers for Disease Control and Prevention.

LifeScienceHistory.com offers three advertising package options. Each package lnclude at least two digital images for multiple page placements and maximum exposure! Rates range from just $300 to $500 per month.